Latest News
RayBiotech to Use Quanterix' Simoa Technology to Enhance Immunoassay Offering
31 March 2015 - - US-based diagnostics developer RayBiotech, Inc has adopted US-based diagnostics company Quanterix Corp.'s Simoa technology to deploy as part of their solutions for biomarker discovery and testing, Quanterix said on Tuesday. Under the deal, RayBiotech will leverage its catalog of antibodies and experience with developing protein assays to offer its customers services that complement Quanterix' own Simoa Accelerator offering based in Lexington, Massachusetts. The Simoa Accelerator lab allows researchers to access its technology to run their samples on Simoa assays, convert their existing assays to Simoa for greater sensitivity, or to have custom assays developed by the Quanterix team for specific markers of interest. In 2001, RayBiotech launched the first commercially available cytokine antibody array with a focus on translating scientific knowledge into improved health. RayBiotech continues to develop high-throughput platforms for identifying disease mechanisms, screening and validation of biomarkers and identification of drug targets. A spin-off from Emory University, RayBiotech is privately owned, with headquarters in metro Atlanta, Georgia. Quanterix is a developer of tools in high definition diagnostics. Its Simoa platform uses single molecule measurements to access previously undetectable proteins.
Login
Username:

Password: